Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940895 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
A Phase 2 study, sponsored by Narrows Institute for Biomedical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06940895: Completed Phase 2 study, sponsored by Narrows Institute for Biomedical Research.
NCT06940895 is a Phase 2 study that has completed, run by Narrows Institute for Biomedical Research. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06940895, a Phase 2 study, has completed, sponsored by Narrows Institute for Biomedical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Primary Outcome
Improvement in the Melanin(M) index from baseline to 12 weeks of treatment. The M index is positively correlated with a darker skin color and ranges from 0-999.
Interventions
- DRUG Sirolimus 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 2 |
What the finished NCT06940895 record still lists
NCT06940895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Sirolimus 0.2% is the first listed.
NCT06940895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06940895 about?
NCT06940895 is a clinical study titled "Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans". The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
What is the current status of trial NCT06940895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-03-01. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT06940895?
The interventions under investigation include: Sirolimus 0.2% (DRUG).
Who is sponsoring clinical trial NCT06940895?
This trial is sponsored by Narrows Institute for Biomedical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06940895's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI